T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.
This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the ...
GlobalData on MSN
BMS and Microsoft partner for AI-based lung cancer detection
The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.
This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.
The "Electric Vehicle Battery Management System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. The Electric ...
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...
GlobalData on MSN
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM
The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.
Peter Bains, Managing Director and CEO, Syngene International Ltd., said, "Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is anchored in scientific excellence, ...
Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.
Clinical Trials Arena on MSN
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff
BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback